Influenza Drug Global Market Report 2025

Description

An influenza drug is a medication designed to prevent or treat influenza (flu) by targeting the influenza virus. These drugs function through various mechanisms, including inhibiting viral replication, preventing viral entry into host cells, or enhancing the immune response against the virus.

The main categories of influenza drugs are influenza A, influenza B, and influenza C. Influenza A infects humans and multiple animal species, causing seasonal flu outbreaks and occasionally pandemics. Administration routes include oral, intranasal, intravenous, intramuscular, and subcutaneous delivery. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and comprise classes such as neuraminidase inhibitors, cap-dependent endonuclease inhibitors, fusion inhibitors, M2 ion channel inhibitors, host cell protease inhibitors, immunomodulatory agents, RNA polymerase inhibitors, hemagglutinin stem binders, cytokine inhibitors, and host factor-targeting agents. End users include hospitals and clinics, pharmacies, vaccination centers, research institutions, government health agencies, long-term care facilities, community health centers, and corporate health programs.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The influenza drug market research report is one of a series of new reports from The Business Research Company that provides influenza drug market statistics, including influenza drug industry global market size, regional shares, competitors with a influenza drug market share, detailed influenza drug market segments, market trends and opportunities, and any further data you may need to thrive in the influenza drug industry. This influenza drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The influenza drug market size has grown strongly in recent years. It will grow from $0.98 billion in 2024 to $1.04 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth observed during the historic period can be attributed to the increasing frequency of seasonal influenza outbreaks, rising healthcare expenditure, growing public awareness of vaccination, expanded use of antiviral drugs, and the implementation of government immunization programs.

The influenza drug market size is expected to see strong growth in the next few years. It will grow to $1.32 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The anticipated growth in the forecast period can be linked to the rising prevalence of influenza-like illnesses, improved global healthcare access, expansion of healthcare infrastructure in emerging markets, increasing demand for combination therapies, and a stronger emphasis on preventive healthcare. Key trends expected in the forecast period include innovations in vaccine development, advancements in diagnostic technologies, development of next-generation antivirals, progress in antiviral research, and improvements in drug delivery systems.

The rising incidence of influenza infections is expected to drive growth in the influenza drug market in the coming years. Influenza is a contagious respiratory illness caused by influenza viruses, producing symptoms such as fever, cough, sore throat, and body aches. The increasing incidence of influenza infections is driven by frequent viral mutations, which reduce vaccine effectiveness and heighten population vulnerability to outbreaks. Influenza drugs help control the spread of infections and reduce disease severity, providing essential treatment options for affected individuals. For example, in September 2023, the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, reported that during the 2022-2023 season, influenza virus infections in the United States led to an estimated 31 million symptomatic illnesses, 14 million medical visits, 360,000 hospitalizations, and 21,000 deaths. Consequently, the growing incidence of influenza infections is propelling demand for influenza drugs.

Companies in the influenza drug market are also advancing treatment technologies to improve patient outcomes and compliance. Innovations in drug formulation, for instance, allow active pharmaceutical ingredients to be combined with excipients to create medications with enhanced properties. In August 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, launched Baloxavir Marboxil for Suspension, a strawberry-flavored, single-dose oral antiviral designed specifically for children. The formulation allows for accurate weight-based dosing, making home administration easier and improving adherence. While this innovation enhances pediatric influenza treatment and ease of use, resistance may still emerge over time, particularly in young patients.

In July 2024, GlaxoSmithKline plc (GSK), a Netherlands-based pharmaceutical company, partnered with CureVac N.V., a Germany-based biotechnology company, to advance mRNA vaccine development. Through this collaboration, GSK aims to accelerate the development of COVID-19 and influenza vaccine candidates, strengthen its mRNA vaccine platform, and expand its infectious-disease pipeline.

Major players in the influenza drug market are F. Hoffmann-La Roche Ltd., Pfizer Inc., AstraZeneca PLC, GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Moderna Inc., BioNTech SE, Shionogi & Co. Ltd., Green Cross Corp, Emergent BioSolutions Inc., Novavax Inc., Hualan Biological Engineering Inc., Serum Institute of India Pvt. Ltd., CSL Seqirus Pty Ltd., BioCryst Pharmaceuticals, Inc., SAB Biotherapeutics Inc., Viriom Inc., Osivax SAS, Cocrystal Pharma Inc., Sinovac Biotech Ltd.

North America was the largest region in the influenza drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in influenza drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the influenza drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The influenza drug market consists of sales of oseltamivir phosphate, rimantadine, zanamivir, baloxavir marboxil and favipiravir (avigan or fabiflu). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Influenza Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on influenza drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for influenza drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The influenza drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Influenza A; Influenza B; Influenza C
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By Route Of Administration: Oral; Intranasal; Intravenous; Intramuscular; Subcutaneous
4) By Mechanism Of Action: Neuraminidase Inhibitors; Cap-Dependent Endonuclease Inhibitors; Fusion Inhibitors; M2 Ion Channel Inhibitors; Host Cell Protease Inhibitors; Immunomodulatory Agents; Ribonucleic Acid (RNA) Polymerase Inhibitors; Hemagglutinin Stem Binders; Cytokine Inhibitors; Host Factor Targeting
5) By End-User: Hospitals And Clinics; Pharmacies; Vaccination Centers; Research Institutions; Government Health Agencies; Long-Term Care Facilities; Community Health Centers; Corporate Health Programs
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Pfizer Inc.; AstraZeneca PLC; GlaxoSmithKline plc; Daiichi Sankyo Co. Ltd.; Moderna Inc.; BioNTech SE; Shionogi & Co. Ltd.; Green Cross Corp; Emergent BioSolutions Inc.; Novavax Inc.; Hualan Biological Engineering Inc.; Serum Institute of India Pvt. Ltd.; CSL Seqirus Pty Ltd.; BioCryst Pharmaceuticals, Inc.; SAB Biotherapeutics Inc.; Viriom Inc.; Osivax SAS; Cocrystal Pharma Inc.; Sinovac Biotech Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37788

1. Executive Summary

2. Influenza Drug Market Characteristics

3. Influenza Drug Market Trends And Strategies

4. Influenza Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Influenza Drug Growth Analysis And Strategic Analysis Framework

5.1. Global Influenza Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Influenza Drug Market Growth Rate Analysis
5.4. Global Influenza Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Influenza Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Influenza Drug Total Addressable Market (TAM)

6. Influenza Drug Market Segmentation

6.1. Global Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Influenza A
Influenza B
Influenza C
6.2. Global Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.3. Global Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intranasal
Intravenous
Intramuscular
Subcutaneous
6.4. Global Influenza Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Neuraminidase Inhibitors
Cap-Dependent Endonuclease Inhibitors
Fusion Inhibitors
M2 Ion Channel Inhibitors
Host Cell Protease Inhibitors
Immunomodulatory Agents
Ribonucleic Acid (RNA) Polymerase Inhibitors
Hemagglutinin Stem Binders
Cytokine Inhibitors
Host Factor Targeting
6.5. Global Influenza Drug Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Pharmacies
Vaccination Centers
Research Institutions
Government Health Agencies
Long-Term Care Facilities
Community Health Centers
Corporate Health Programs

7. Influenza Drug Market Regional And Country Analysis

7.1. Global Influenza Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Influenza Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Influenza Drug Market

8.1. Asia-Pacific Influenza Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Influenza Drug Market

9.1. China Influenza Drug Market Overview
9.2. China Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Influenza Drug Market

10.1. India Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Influenza Drug Market

11.1. Japan Influenza Drug Market Overview
11.2. Japan Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Influenza Drug Market

12.1. Australia Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Influenza Drug Market

13.1. Indonesia Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Influenza Drug Market

14.1. South Korea Influenza Drug Market Overview
14.2. South Korea Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Influenza Drug Market

15.1. Western Europe Influenza Drug Market Overview
15.2. Western Europe Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Influenza Drug Market

16.1. UK Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Influenza Drug Market

17.1. Germany Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Influenza Drug Market

18.1. France Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Influenza Drug Market

19.1. Italy Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Influenza Drug Market

20.1. Spain Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Influenza Drug Market

21.1. Eastern Europe Influenza Drug Market Overview
21.2. Eastern Europe Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Influenza Drug Market

22.1. Russia Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Influenza Drug Market

23.1. North America Influenza Drug Market Overview
23.2. North America Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Influenza Drug Market

24.1. USA Influenza Drug Market Overview
24.2. USA Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Influenza Drug Market

25.1. Canada Influenza Drug Market Overview
25.2. Canada Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Influenza Drug Market

26.1. South America Influenza Drug Market Overview
26.2. South America Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Influenza Drug Market

27.1. Brazil Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Influenza Drug Market

28.1. Middle East Influenza Drug Market Overview
28.2. Middle East Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Influenza Drug Market

29.1. Africa Influenza Drug Market Overview
29.2. Africa Influenza Drug Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Influenza Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Influenza Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Influenza Drug Market Competitive Landscape And Company Profiles

30.1. Influenza Drug Market Competitive Landscape
30.2. Influenza Drug Market Company Profiles
- 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Daiichi Sankyo Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Influenza Drug Market Other Major And Innovative Companies

31.1. Moderna Inc.
31.2. BioNTech SE
31.3. Shionogi & Co.Ltd.
31.4. Green Cross Corp
31.5. Emergent BioSolutions Inc.
31.6. Novavax Inc.
31.7. Hualan Biological Engineering Inc.
31.8. Serum Institute of India Pvt. Ltd.
31.9. CSL Seqirus Pty Ltd.
31.10. BioCryst Pharmaceuticals, Inc.
31.11. SAB Biotherapeutics Inc.
31.12. Viriom Inc.
31.13. Osivax SAS
31.14. Cocrystal Pharma Inc.
31.15. Sinovac Biotech Ltd.

32. Global Influenza Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Influenza Drug Market

34. Recent Developments In The Influenza Drug Market

35. Influenza Drug Market High Potential Countries, Segments and Strategies

35.1 Influenza Drug Market In 2029 - Countries Offering Most New Opportunities
35.2 Influenza Drug Market In 2029 - Segments Offering Most New Opportunities
35.3 Influenza Drug Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer